Quarterly ResultMay 7, 2026, 06:13 AM
Zai Lab Q1 Revenue $99.6M, Net Loss $51.0M; Strong Pipeline Progress
AI Summary
Zai Lab Limited reported total revenues of $99.6 million for the first quarter of 2026, a 6% decrease year-over-year, primarily due to competitive impacts on ZEJULA and pricing adjustments for VYVGART. The company's net loss increased to $51.0 million. Despite the financial decline, Zai Lab highlighted significant pipeline progress, including standout data for zocilurtatug pelitecan (zoci) in SCLC and epNECs, new collaborations for zoci, positive Phase 3 readouts for povetacicept in IgAN and elegrobart in TED, and ongoing preparations for the KarXT launch in China.
Key Highlights
- Total revenue decreased 6% to $99.6 million in Q1 2026 from $106.5 million in Q1 2025.
- Net loss increased to $51.0 million in Q1 2026 from $48.4 million in Q1 2025.
- Zocilurtatug pelitecan (zoci) showed 62.5% intracranial ORR in SCLC patients with brain metastases.
- Zoci demonstrated 38.2% confirmed ORR across extrapulmonary neuroendocrine carcinomas (epNECs).
- Collaborations were announced with Amgen and Boehringer Ingelheim for zoci combination therapies.
- ZL-1503 preclinical data supported less frequent dosing and broad potential in atopic diseases.
- Povetacicept Phase 3 trial met its primary endpoint with a 52.0% UPCR reduction in IgA nephropathy.
- Elegrobart Phase 3 trials showed 50-63% proptosis responder rates in active and chronic TED.